Patents by Inventor Marc G. Achen

Marc G. Achen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
    Publication number: 20080145366
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: March 28, 2007
    Publication date: June 19, 2008
    Applicants: Licentia, Ltd.
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
    Patent number: 7122654
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: October 17, 2006
    Assignees: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd.
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven Stacker, Kari Alitalo
  • Antibodies to truncated VEGF-D and uses thereof
    Patent number: 7097986
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: August 29, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
    Patent number: 7045133
    Abstract: Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop 1, 2 or 3 of VEGF-D, and methods of making them are described as well as pharmaceutical compositions containing them and methods utilizing them.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: May 16, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Richard A. Hughes, Steven Stacker, Angela Cendron
  • Use of VEGF-C to prevent restenosis
    Patent number: 6958147
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 25, 2005
    Assignees: Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Vascular endothelial growth factor D(VEGF-D) antibodies and vectors, and methods of use
    Publication number: 20040175730
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: November 12, 2003
    Publication date: September 9, 2004
    Applicants: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd., OY
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Antibodies to truncated VEGF-D and uses thereof
    Publication number: 20040141917
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Application
    Filed: February 18, 2004
    Publication date: July 22, 2004
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Antibodies to truncated VEGF-D and uses thereof
    Patent number: 6730489
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 4, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Growth factor
    Patent number: 6689580
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: February 10, 2004
    Assignees: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd.
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Vascular endothelial growth factor D(VEGF-D) antibodies and vectors, and methods of use
    Publication number: 20030125537
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: June 5, 2002
    Publication date: July 3, 2003
    Applicant: Ludwig Institute for Cancer Research and Helsinki University Licensing Ltd. OY
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
    Publication number: 20030114658
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: October 22, 2002
    Publication date: June 19, 2003
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS
    Publication number: 20020127222
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: December 23, 1998
    Publication date: September 12, 2002
    Inventors: MARC G. ACHEN, STEVEN ALAN STACKER, KARI ALITALO
  • VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
    Publication number: 20020065218
    Abstract: Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop 1, 2 or 3 of VEGF-D, and methods of making them are described as well as pharmaceutical compositions containing them and methods utilizing them.
    Type: Application
    Filed: January 18, 2001
    Publication date: May 30, 2002
    Inventors: Marc G. Achen, Richard A. Hughes, Steven Stacker, Angela Cendron
  • Antibodies to truncated VEGF-D and thereof
    Patent number: 6383484
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Vascular endothelial growth factor-D (VEGF-D) polypeptides
    Patent number: 6235713
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: May 22, 2001
    Assignees: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd.
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo